On the Frontlines of Psoriasis

Unlocking the Potential of TYK2 Inhibitors in Plaque Psoriasis

15 min · 16. jan. 2026
episode Unlocking the Potential of TYK2 Inhibitors in Plaque Psoriasis cover

Beskrivelse

Guest: Christopher Bunick, MD, PhD, FAAD Host: Ryan Quigley With high selectivity, durable response, and once-daily dosing, next-generation TYK2 inhibitors offer a promising oral option for patients with moderate-to-severe plaque psoriasis. Ryan Quigley sits down with Dr. Christopher Bunick, Associate Professor of Dermatology and Translational Biomedicine at Yale University School of Medicine, to learn more about how these agents may align with evolving patient preferences and expand options beyond injectables.

Kommentarer

0

Vær den første til at kommentere

Tilmeld dig nu og bliv en del af On the Frontlines of Psoriasis-fællesskabet!

Kom i gang

1 måned kun 9 kr.

Derefter 99 kr. / måned · Opsig når som helst.

  • Podcasts kun på Podimo
  • 20 lydbogstimer pr. måned
  • Gratis podcasts

Alle episoder

28 episoder